TAK-659 + gemcitabine

**TAK-659 + gemcitabine** is an investigational combination therapy comprising TAK-659, a small molecule dual inhibitor targeting spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3), together with gemcitabine, a nucleoside analog antineoplastic agent. - **TAK-659 (mivavotinib)** blocks SYK and FLT3 signaling pathways that are crucial in hematologic malignancies and some solid tumors; SYK is involved in B-cell receptor signaling and drug resistance, while FLT3 is commonly mutated in certain leukemias, promoting tumor growth[2][5]. - **Gemcitabine** is phosphorylated intracellularly, interfering with DNA synthesis and cell replication. The combination is intended for use in oncology, notably in clinical trials for high-risk diffuse large B-cell lymphoma (DLBCL) and solid tumors, aiming to maximize anti-tumor activity and overcome chemoresistance via synergistic mechanisms[2][5]. TAK-659 is developed by Takeda.

Brand names

mivavotinibGemzar

Other names

TAK-659TAK659TAK 659gemcitabinemivavotinibGemzar